Parties involved in federally-filed testosterone lawsuits are scheduled to meet next week in the Northern District of Illinois to discuss a possible coordination with claims centralized in various state jurisdictions, according to court documents.

The federal proceeding’s status conference will take place on December 8th, where matters related to claims against the makers of AndroGel, Testim, Axiron and other medications, will be discussed. Among other items listed on the Court’s agenda will be a review of competing proposals for whether to coordinate lawsuits filed in jurisdictions located in Illinois, Missouri, Pennsylvania, California and other states. There are right now more than 250 testosterone cases now centralized in the U.S. District Court, Northern District of Illinois, where the multidistrict litigation is underway. This discussion will follow a request from the U.S. District Judge overseeing federal lawsuits involving AndroGel, Testim and other products that parties work together to coordinate claims in the federal MDL, as well as state-filed cases.

A recent joint status report reflects the parties’ lack of agreement on the issue as of December 4th, though, which may prove the Court’s status conference discussion to be a vitally important one for plaintiffs whose cases are now pending in state litigations. Plaintiffs’ attorneys currently serving in the MDL issued a submission on December 3rd stating that its Executive Committee did not support the coordination of claims, because any orders on state court judges would be difficult to enforce.

Testosterone Plaintiffs Don’t See Need for Coordination with State Courts

The federal testosterone MDL is moving forward quickly, with the first bellwether trials slated to begin in late 2016 and early 2017. The small group of cases will similarly involve heart-related injuries allegedly caused by AndroGel, a prescription hormone therapy marketed by Abbott Laboratories and AbbVie, Inc.

Testosterone lawsuits involving this medication, as well as several others in the Illinois litigation, were filed by men who claim to have sustained heart attacks, strokes, blood clots or another injury allegedly caused by their use. All these claims were filed after a federal warning from the U.S. Food and Drug Administration (FDA) noted the findings of research that found an increased risk for cardiovascular injuries in younger men with a pre-existing history of heart disease and all men older than 65.

Consider a Testosterone Lawsuit

Call a testosterone lawyer today for more information about claims involving AndroGel and other hormone-raising therapies at (877) 779-114.

Published December 8, 2014 by